5240752026-04-012026-06-305240752026-04-012026-06-30in-capmkt:OtherExpenses1Member5240752026-04-012026-06-30

ItemsThatWillNotBeReclassifiedToProfitAndLoss1

iso4217:INRiso4217:INRxbrli:shares

524075

ALBERTDAVD

NOTLISTED

INE155C01010

ALBERT DAVID LIMITED

Main Board

Equity

2026-04-01

2027-03-31

2026-08-06

2026-07-24

INR

Lakhs

Quarterly

First quarter

Single segment

pharmacueticals

2026-08-06

11:35:00

2026-08-06

15:15:00

Not applicable

false

The disclosure is not applicable to us.

2026-04-01

2026-06-30

Unaudited

Standalone

1013355000

279623000

1292978000

183319000

123948000

54601000

255524000

5164000

22864000

289618000

935038000

357940000

11979000

25983000

37962000

319978000

-10239000

309739000

57072000

56.07

1. The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 6th August, 2026. The Limited Review for the quarter ended 30th June, 2026 has been carried out by Statutory Auditors, as required under Regulation 33 of SEBI (LO&DR) Regulations, 2015. 2. The Statutory Auditors of the Company have issued an unmodified review report on the Unaudited Financial Results for the quarter ended 30th June, 2026. 3. The Company is engaged in the manufacturing of pharmaceuticals and has only one reportable segment in accordance with Ind AS-108 " Operating Segments". 4. Figures for the quarter ended 31st March, 2026 are the balancing figures between the audited figures in respect of the full financial year and the figures upto end of third quarter. 5. Figures for the previous periods are regrouped to conform to the figures of the current period as and when required in limited context of format of financial results and disclosures thereon specified by SEBI.

Other Expenses

289618000

Items that will not be reclassified to profit or loss

-13682000

-3443000

-10239000